Sara M. Tolaney, MD, MPH

Articles

Dr. Tolaney on Tailoring HER2-Directed Therapy in Breast Cancer

July 19th 2021

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer.

Dr. Tolaney on the Need to Develop Additional Biomarkers in mTNBC

January 14th 2021

Sara M. Tolaney, MD, MPH, discusses the need to develop additional biomarkers of response in metastatic triple-negative breast cancer.

Dr. Tolaney on the Safety Profile of SAR439859 in ER+/HER2- Metastatic Breast Cancer

December 10th 2020

Sara M. Tolaney, MD, MPH, discusses the safety profile of SAR439859 in estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Tolaney on Escalating Versus De-Escalating Therapies in HER2+ Breast Cancer

October 23rd 2020

Sara M. Tolaney, MD, MPH, discusses escalating versus de-escalating therapies in HER2-positive breast cancer.

Dr. Tolaney on Data With Trastuzumab Deruxtecan in HER2+ Breast Cancer Brain Metastases

October 22nd 2020

Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.

Dr. Tolaney on the APT and ATEMPT Trials in Stage I HER2+ Breast Cancer

October 3rd 2020

Sara M. Tolaney, MD, MPH, discusses the phase 2 APT and ATEMPT trials in stage I HER2-positive breast cancer.

Dr. Tolaney on the Evolution of Treatment in HER2+ Breast Cancer

October 1st 2020

Sara M. Tolaney, MD, MPH, discusses the evolution of treatment in HER2-positive breast cancer.

Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer

July 17th 2020

Sara M. Tolaney, MD, MPH, discusses appropriately deescalating treatment to reduce toxicities in stage I HER2-positive breast cancer.

Dr. Tolaney on CNS Recurrence in HER2+ Breast Cancer

June 10th 2020

Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.

Dr. Tolaney on CNS Recurrence in HER2+ Breast Cancer

June 9th 2020

Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.

Dr. Tolaney on Sequencing Strategies in Metastatic HER2+ Breast Cancer

May 6th 2020

Sara M. Tolaney, MD, MPH, discusses sequencing strategies in metastatic HER2-positive breast cancer.

Dr. Tolaney on Remaining Questions With CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

May 5th 2020

Sara M. Tolaney, MD, MPH, discusses remaining questions with CDK4/6 inhibitors in hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr. Tolaney on Sequencing Questions in Breast Cancer

April 7th 2020

Sara M. Tolaney, MD, MPH, discusses remaining sequencing questions in breast cancer.

Dr. Tolaney on Navigating Adjuvant Therapy in Early-Stage HER2+ Breast Cancer

March 11th 2020

Sara M. Tolaney, MD, MPH, associate director, Susan F. Smith’s Center for Women’s Cancers, director, Clinical Trials, Breast Oncology, senior physician, Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses considerations for adjuvant therapy in patients with early-stage HER2-positive breast cancer.

Dr. Tolaney on Novel Approaches in Treating HER2-Positive Breast Cancer

March 4th 2020

Sara M. Tolaney, MD, MPH, discusses novel approaches in treating patients with HER2-positive breast cancer.

Dr. Tolaney on the Advantages of ctDNA Versus Tissue Biopsy in Breast Cancer

January 25th 2020

Sara M. Tolaney, MD, MPH, discusses the advantages of circulating tumor DNA versus tissue biopsy in breast cancer.

Dr. Tolaney on Presence of PIK3CA and ESR1 Mutations in MONARCH 2 Trial in Breast Cancer

April 26th 2019

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the presence of PIK3CA mutations and ESR1 mutations in patients with breast cancer enrolled in the phase III MONARCH 2 trial.

Dr. Tolaney on Recent Advances in HR-Positive Breast Cancer

September 27th 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses recent advances in the treatment of patients with hormone receptor-positive breast cancer.

Dr. Tolaney Reflects on Data from the PERSEPHONE Trial

September 18th 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, reflects on data from the PERSEPHONE trial in HER2-positive breast cancer.

Dr. Tolaney Discusses Unmet Needs in ER+ Breast Cancer

August 31st 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses unmet needs in the treatment of patients with estrogen receptor (ER)-positive breast cancer.